Traders should monitor upcoming 2026 catalysts, particularly EMA decisions on OJEMDA and MIPLYFFA and Phase 3 data for ersodetug, which could drive further royalty upside. The company’s shift to positive operating cash flow and active buybacks support shareholder value, but litigation risk with Janssen remains a watch item.
How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 18 $27.35entry
- T+1 · 8mo ago +5.16%α +5.42% · $28.76
- T+5 · 8mo ago +10.42%α +11.14% · $30.20
- T+20 · 7mo ago +44.83%α +38.78% · $39.61
- T+60 · 5mo ago +52.83%α +41.31% · $41.80
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
XOMA Royalty Corporation reported strong full-year 2025 financial results with revenue up 83% YoY to $52.1 million and a swing to net income of $31.7 million from a $13.8 million loss in 2024, driven by higher royalty and milestone receipts. The company repurchased $16.0 million in shares and expanded its portfolio with 22 new assets and seven acquisitions, while also securing potential future upside from late-stage pipeline catalysts in 2026.
Key Financial Metrics
Key Facts
- Full-year 2025 revenue: $52.1 million (up 83% YoY from $28.5 million)
- Net income: $31.7 million in 2025 vs. net loss of $13.8 million in 2024
- Achieved $50.5 million in cash receipts: $33.6 million in royalties, $16.9 million in milestones
- Repurchased and retired 648,048 shares for $16.0 million in 2025
- Completed seven acquisitions, adding $11.7 million in non-dilutive capital and exposure to up to $1.1 billion in potential milestones
- Takeda deal expansion: up to $852.6 million in potential milestones and low to mid-single-digit royalties on nine assets
- Key 2026 catalysts: Phase 3 data for ersodetug in tumor HI, EMA decisions on OJEMDA and MIPLYFFA, and Phase 2b data for volixibat in PSC
Financial Impact
Revenue increased by $23.6 million YoY, with net income improving by $45.5 million. Operating cash flow turned positive at $2.9 million in 2025 vs. -$13.7 million in 2024.
Risk Factors
- Clinical setbacks in key pipeline assets (e.g., ersodetug failed to meet statistical significance in congenital HI)
- Ongoing litigation with Janssen Biotech with uncertain outcome and potential for continued legal costs
- Dependence on third-party drug development success and regulatory approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257974 |
Track record
8 reports on XOMA
The track record builds as more bullish or bearish reports settle.
Filters
- Jul 27, 202616w ago 15-12G Bearish 7/10 No price data
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $40.17 to $40.17 · 0.00% +0.47% vs SPY
- Jun 12, 202622w ago DEFA14A Bullish 8/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
- Jun 12, 202622w ago 8-K Neutral 4/10 Entry $41.95 to $42.00 ▲ +0.12% +1.50% vs SPY
- Mar 18, 202634w ago Press Release Neutral 3/10 Entry $28.76 to $30.53 ▲ +6.15% +8.37% vs SPY
- Mar 18, 202634w ago 8-K Neutral 4/10 Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
- Mar 18, 202634w ago Press Release Bullish 8/10 Viewing Entry $27.35 to $30.20 ▲ +10.42% +11.14% vs SPY
- Mar 12, 202635w ago Press Release Neutral 3/10 Entry $26.86 to $28.76 ▲ +7.07% +8.05% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers